Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions.

Mol Cell

INSERM U830, Équipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France; Institut Curie, PSL Research University, Sorbonne Université, CNRS UMR 3664, Laboratoire Dynamique du Noyau, 75005

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Many cancers are characterized by gene fusions encoding oncogenic chimeric transcription factors (TFs) such as EWS::FLI1 in Ewing sarcoma (EwS). Here, we find that EWS::FLI1 induces the robust expression of a specific set of novel spliced and polyadenylated transcripts within otherwise transcriptionally silent regions of the genome. These neogenes (NGs) are virtually undetectable in large collections of normal tissues or non-EwS tumors and can be silenced by CRISPR interference at regulatory EWS::FLI1-bound microsatellites. Ribosome profiling and proteomics further show that some NGs are translated into highly EwS-specific peptides. More generally, we show that hundreds of NGs can be detected in diverse cancers characterized by chimeric TFs. Altogether, this study identifies the transcription, processing, and translation of novel, specific, highly expressed multi-exonic transcripts from otherwise silent regions of the genome as a new activity of aberrant TFs in cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2022.04.019DOI Listing

Publication Analysis

Top Keywords

oncogenic chimeric
8
chimeric transcription
8
transcription factors
8
transcription processing
8
processing translation
8
cancers characterized
8
silent regions
8
regions genome
8
transcription
4
factors drive
4

Similar Publications

Multiplex engineering using microRNA-mediated gene silencing in CAR T cells.

Front Immunol

September 2025

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Background: Multiplex gene-edited chimeric antigen receptor (CAR) T-cell therapies face significant challenges, including potential oncogenic risks associated with double-strand DNA breaks. Targeted microRNAs (miRNAs) may provide a safer, functional, and tunable alternative for gene silencing without the need for DNA editing.

Methods: As a proof of concept for multiplex gene silencing, we employed an optimized miRNA backbone and gene architecture to silence T-cell receptor (TCR) and major histocompatibility complex class I (MHC-I) in mesothelin-directed CAR (M5CAR) T cells.

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR)-T therapy has shown significant success in the treatment of relapsed or refractory acute lymphoblastic leukemia (r/r ALL). However, its role in patients with the TCF3-PBX1 fusion gene - which generally exhibit poor prognostic indicators - remains uncertain. From September 2016 to March 2023, 7 patients with r/r ALL positive for the TCF3-PBX1 fusion gene underwent CD19 CAR-T-cell therapy at the First Affiliated Hospital of Zhejiang University School of Medicine.

View Article and Find Full Text PDF

Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuR.

JACS Au

August 2025

The Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91121, Israel.

Hu antigen R (HuR), also known as ELAVL1, is an RNA-binding protein (RBP) that plays a pivotal role in promoting oncogene expression by stabilizing oncogenic mRNAs. Elevated cytoplasmic levels of HuR are strongly associated with critical processes in breast cancer progression, including enhanced proliferation, survival, and metastasis. Targeting HuR presents a promising therapeutic strategy for aggressive subtypes of breast cancer.

View Article and Find Full Text PDF

NTRK expression and its clinical significance in pancreatic neuroendocrine tumors.

Discov Oncol

August 2025

Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, 58, Zhongshan Road II, Guangzhou, 510080, China.

Background: The neurotrophic TRK family, which includes NTRK1, 2, and 3, could be the oncogenic driving force in various cancers, when they undergo fusion mutations with other genes and form a chimeric oncoprotein. In our study, we aimed to explore the expression and gene alterations of NTRK in pancreatic neuroendocrine tumors (pNETs).

Methods: Immunohistochemistry (IHC) staining was utilized to assess NTRK expression in pNETs, using pan-TRK cocktail (clone LBP2-NTRK).

View Article and Find Full Text PDF

[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].

Zhonghua Yi Xue Za Zhi

September 2025

Department of Laboratory Medicine, Hebei Yanda Ludaopei Hospital, Langfang 065201, China Beijing Ludaopei Institute of Hematology, Department of Pathology &Laboratory Medicine, Beijing Ludaopei Hospital, Beijing 100176, China.

A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years.

View Article and Find Full Text PDF